TaiMed Biologics Inc. announced US FDA approved the sBLA for the IV Push administration of the loading dose of Trogarzo. Relationship to the Company: head office, Cause of occurrence: On October 3, 2022, the FDA approved a 30-second Intravenous (?IV?) Push method of administration for the maintenance dose of Trogarzo. In order to provide further dosing convenient to patients and practioners for the administration of Trogarzo, TaiMed?s marketing partner, Theratechnologies Inc. filed an supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the IV Push administration of the loading dose of Trogarzo in July 2024.

The FDA has approved the application.